BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23589555)

  • 1. Designing transformative clinical trials in the cancer genome era.
    Sleijfer S; Bogaerts J; Siu LL
    J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of genomics in clinical trial design.
    Simon R
    Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future of clinical genomics in pediatric oncology.
    Janeway KA; Place AE; Kieran MW; Harris MH
    J Clin Oncol; 2013 May; 31(15):1893-903. PubMed ID: 23589558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tumor sequencing on the use of anticancer drugs.
    Thomas F; Desmedt C; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):347-56. PubMed ID: 24709974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic medicine frontier in human solid tumors: prospects and challenges.
    Dienstmann R; Rodon J; Barretina J; Tabernero J
    J Clin Oncol; 2013 May; 31(15):1874-84. PubMed ID: 23589551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From genomic landscapes to personalized cancer management-is there a roadmap?
    Swanton C; Caldas C
    Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New omics information for clinical trial utility in the primary setting.
    Damia G; Broggini M; Marsoni S; Venturini S; Generali D
    J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genomics and clinical research for breast cancer].
    Bertucci F; Birnbaum D
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microarrays to identify new therapeutic strategies for cancer.
    Sears C; Armstrong SA
    Adv Cancer Res; 2007; 96():51-74. PubMed ID: 17161676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genomic markers and anticancer chemotherapy].
    Nishiyama M
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing the future shape of breast cancer diagnosis, prognosis and treatment.
    Dowsett M
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S27-9. PubMed ID: 15597218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.